Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
Does tamoxifen increase one’s risk of developing uterine cancer in patients who’ve undergone endometrial ablation or a D&C?
Related Questions
Would you offer adjuvant chemotherapy for triple negative invasive papillary carcinoma of breast?
What is your preferred sequencing of adjuvant chemotherapy and PMRT for node + breast cancer?
How would you treat a T2N1 ER 90%, PR 10 %, Her 2 negative Breast cancer in premenopausal women with tumor appearing abutting pectoralis fascia with loss of fat plane with a concern for a positive surgical margin? would you consider neoadjuvant treatment ?
Would you discontinue or dose-reduce Tamoxifen in a patient that developed hepatic steatosis?
When do you recommend preoperative chemotherapy or hormonal therapy for ER+ breast cancer?
would you recommend ALND to a postmenopausal female with one positive lymph node and small volume metastasis in other Lymph nodes?
What recommendations would you make for a patient on long-term phenytoin due to epilepsy with a newly diagnosed breast cancer requiring doxorubicin as part of her chemotherapy?
What are your top takeaways in Breast Cancer from ASCO 2024?
With the recent FDA approval of adjuvant ribociclib, how are you deciding between ribociclib and abemaciclib for high risk HR+/HER2− early breast cancer?
How do you manage a patient with early stage HER2+ breast cancer patient who progressed on mastectomy after completing neoadjuvant TCHP?
